Weiping Guo became the CEO of Genertec Universal Medical Group Company Limited (HKG:2666) in 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid.
How Does Weiping Guo’s Compensation Compare With Similar Sized Companies?
At the time of writing our data says that Genertec Universal Medical Group Company Limited has a market cap of HK$10.5b, and is paying total annual CEO compensation of CN¥4m. That’s a notable increase of 17% on last year. As part of our analysis we looked at companies in the same jurisdiction, with market capitalizations of CN¥7.0b to CN¥22.3b. The median total CEO compensation was CN¥3m.
That means Weiping Guo receives fairly typical remuneration for the CEO of a company that size. While this data point isn’t particularly informative alone, it gains more meaning when considered with business performance.
You can see, below, how CEO compensation at Genertec Universal Medical Group has changed over time.
Is Genertec Universal Medical Group Company Limited Growing?
Genertec Universal Medical Group Company Limited has increased its earnings per share (EPS) by an average of 19% a year, over the last three years It achieved revenue growth of 24% over the last year.
Overall this is a positive result for shareholders, showing that the company has improved in recent years. It’s a real positive to see this sort of growth in a single year. That suggests a healthy and growing business. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.
Has Genertec Universal Medical Group Company Limited Been A Good Investment?
Genertec Universal Medical Group Company Limited has generated a total shareholder return of 10% over three years, so most shareholders would be reasonably content. But they would probably prefer not to see CEO compensation far in excess of the median.
Weiping Guo is paid around the same as most CEOs of similar size companies.
Shareholder returns could be better but shareholders would be pleased with the positive EPS growth. So considering these factors, we think the CEO pay is probably quite reasonable. CEO pay isn’t the only data point that can tell us about management of a company. So it makes sense to check how long the Board of Directors has been in place.
Of course Genertec Universal Medical Group may not be the best stock to buy. So you may wish to see this free collection of other companies that have high ROE and low debt.
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at firstname.lastname@example.org.